A Phase 2, Open Label Study of PEmigatinib and REtifanlimab in Advanced Dedifferentiated LIposarcoma (PERELI)

NCT06389799 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

33

Enrollment

OTHER

Sponsor class

Conditions

Dedifferentiated Liposarcoma

Interventions

DRUG: Pemigatinib
DRUG: Retifanlimab

Sponsor

Lund University Hospital